Bill
HB 6750
Overview: HB 6750, AN ACT AUTHORIZING THE STATE TO MANUFACTURE CERTAIN GENERIC DRUGS, was introduced on January 27, 2025 and referred to the Joint Committee on General Law.Purpose
Overview: HB 6750, AN ACT AUTHORIZING THE STATE TO MANUFACTURE CERTAIN GENERIC DRUGS, was introduced on January 27, 2025 and referred to the Joint Committee on General Law.
Purpose and Intent: The bill aims to address the high cost of prescription drugs by authorizing the state to manufacture and distribute certain generic medications. The goal is to increase access to affordable healthcare and reduce the financial burden on patients.
Key Provisions:
- Establishes a state-run pharmaceutical manufacturing program to produce generic versions of high-cost brand-name drugs
- Requires the state to prioritize the manufacture of generic drugs for conditions with limited treatment options or where prices have risen significantly
- Directs the state to sell the generic drugs at cost to residents, healthcare providers, and state-run insurance programs
Affected Parties and Impacts: The bill would directly benefit patients who require expensive brand-name medications, as they would have access to more affordable generic alternatives produced by the state. Pharmaceutical companies may be impacted by the state's entry into the generic drug market, which could reduce their profits.
Procedural and Timeline Considerations: The bill has been referred to the Joint Committee on General Law for further consideration. If passed by the committee, it would then move to a full vote in the state legislature.
Compiled from official sources — confirm details with the bill’s official record.
Sign in to ask a question.
